Advertisement

 

 

A potent, selective and orally bioavailable inhibitor of the protein tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models.

A potent, selective and orally bioavailable inhibitor of the protein tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models.
Author Information (click to view)

Krishnan N, Konidaris KF, Gasser G, Tonks NK,


Krishnan N, Konidaris KF, Gasser G, Tonks NK, (click to view)

Krishnan N, Konidaris KF, Gasser G, Tonks NK,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

The Journal of biological chemistry 2017 12 07() pii jbc.C117.819110
Abstract

The protein tyrosine phosphatase PTP1B is a negative regulator of insulin and leptin signaling, and a highly validated therapeutic target for diabetes and obesity. Conventional approaches to drug development have produced potent and specific PTP1B inhibitors, but these inhibitors lack oral bioavailability, which limits their potential for drug development. Here we report that DPM-1001, an analogue of the specific PTP1B inhibitor trodusquemine (MSI-1436), is a potent, specific and orally bioavailable inhibitor of PTP1B. DPM-1001 also chelates copper, which enhanced its potency as a PTP1B inhibitor. DPM-1001 displayed anti-diabetic properties that were associated with enhanced signaling through insulin and leptin receptors in animal models of diet-induced obesity. Therefore, DPM-1001 represents a proof of concept for a new approach to therapeutic intervention in diabetes and obesity. Although the PTPs have been considered undruggable, the findings of this study suggest that allosteric PTP inhibitors may help reinvigorate drug development efforts that focus on this important family of signal transducing enzymes.

Submit a Comment

Your email address will not be published. Required fields are marked *

5 × two =

[ HIDE/SHOW ]